HK1030883A1 - Preventives/remedies for glaucoma - Google Patents

Preventives/remedies for glaucoma

Info

Publication number
HK1030883A1
HK1030883A1 HK01101779A HK01101779A HK1030883A1 HK 1030883 A1 HK1030883 A1 HK 1030883A1 HK 01101779 A HK01101779 A HK 01101779A HK 01101779 A HK01101779 A HK 01101779A HK 1030883 A1 HK1030883 A1 HK 1030883A1
Authority
HK
Hong Kong
Prior art keywords
glaucoma
prophylaxis
treatment
agent
compound
Prior art date
Application number
HK01101779A
Other languages
English (en)
Inventor
Mitsuyoshi Azuma
Yukuo Yoshida
Mitsunori Waki
Masayoshi Uehata
Original Assignee
Senju Pharma Co
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co, Mitsubishi Pharma Corp filed Critical Senju Pharma Co
Priority to HK05102430.9A priority Critical patent/HK1069120A1/xx
Priority to HK05102431.8A priority patent/HK1069121A1/xx
Publication of HK1030883A1 publication Critical patent/HK1030883A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
HK01101779A 1998-08-17 2001-03-12 Preventives/remedies for glaucoma HK1030883A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
HK05102430.9A HK1069120A1 (en) 1998-08-17 2001-03-12 Agent for prophylaxis and treatment of glaucoma
HK05102431.8A HK1069121A1 (en) 1998-08-17 2001-03-12 Agent for prophylaxis and treatment of asthenopia and pseudomyopia

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP24776298 1998-08-17
JP12296099 1999-04-28
PCT/JP1999/004403 WO2000009162A1 (fr) 1998-08-17 1999-08-13 Medicaments preventifs/curatifs pour le glaucome

Publications (1)

Publication Number Publication Date
HK1030883A1 true HK1030883A1 (en) 2001-05-25

Family

ID=26459997

Family Applications (3)

Application Number Title Priority Date Filing Date
HK01101779A HK1030883A1 (en) 1998-08-17 2001-03-12 Preventives/remedies for glaucoma
HK05102430.9A HK1069120A1 (en) 1998-08-17 2001-03-12 Agent for prophylaxis and treatment of glaucoma
HK05102431.8A HK1069121A1 (en) 1998-08-17 2001-03-12 Agent for prophylaxis and treatment of asthenopia and pseudomyopia

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK05102430.9A HK1069120A1 (en) 1998-08-17 2001-03-12 Agent for prophylaxis and treatment of glaucoma
HK05102431.8A HK1069121A1 (en) 1998-08-17 2001-03-12 Agent for prophylaxis and treatment of asthenopia and pseudomyopia

Country Status (12)

Country Link
US (2) US6673812B1 (ja)
EP (3) EP1459743B9 (ja)
JP (2) JP3720264B2 (ja)
KR (1) KR100616466B1 (ja)
CN (2) CN1293878C (ja)
AT (3) ATE527993T1 (ja)
AU (1) AU5198199A (ja)
CA (2) CA2307285C (ja)
DE (1) DE69927936T2 (ja)
ES (3) ES2247822T3 (ja)
HK (3) HK1030883A1 (ja)
WO (1) WO2000009162A1 (ja)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1110553B1 (en) * 1998-08-10 2013-03-27 Asahi Kasei Pharma Corporation Sustained release oral preparations of fasudil hydrochloride
WO2000057913A1 (fr) * 1999-03-25 2000-10-05 Welfide Corporation Prophylaxies/remedes pour la pneumonie interstitielle et la fibrose pulmonaire
AU3328600A (en) * 1999-03-25 2000-10-16 Santen Pharmaceutical Co. Ltd. Ocular tension-lowering agents
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
AU2001293817A1 (en) 2000-09-20 2002-04-02 Merck Patent Gmbh 4-amino-quinazolines
EP1378247B1 (en) * 2001-04-11 2016-08-24 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
JP2003010158A (ja) * 2001-04-26 2003-01-14 Biochemical & Pharmacological Laboratories Inc 眼精疲労モデル、その作製方法、そのモデルを用いた評価方法およびその評価法を用いて選択された薬剤
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
AU2003202263A1 (en) 2002-01-10 2003-07-30 Bayer Healthcare Ag Roh-kinase inhibitors
ATE381557T1 (de) 2002-01-23 2008-01-15 Bayer Pharmaceuticals Corp Rho-kinase inhibitoren
WO2003062225A1 (en) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
US20050245509A1 (en) 2002-08-29 2005-11-03 Santen Pharmacecutical Co., Ltd. Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins
AU2003269413A1 (en) * 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
EP1568382B1 (en) * 2002-11-18 2013-11-06 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND beta-BLOCKER
US7160894B2 (en) * 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
CN100390173C (zh) * 2003-06-06 2008-05-28 旭化成制药株式会社 3环系化合物
US7563906B2 (en) 2003-10-15 2009-07-21 Ube Industries, Ltd. Indazole derivatives
WO2005053683A1 (en) * 2003-11-26 2005-06-16 Duke University A method of preventing or treating glaucoma
US7083783B2 (en) * 2004-02-18 2006-08-01 Wisconsin Alumni Research Foundation Method for treating glaucoma
WO2005102345A1 (en) * 2004-03-30 2005-11-03 Alcon, Inc. Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
FR2868310A1 (fr) * 2004-04-02 2005-10-07 Oreal Utilisation cosmetique d'au moins un inhibiteur de la production et/ou de l'activation des rhoa kinases comme agent destine a detendre les traits et/ou decontracter la peau
EP1752456B1 (en) * 2004-06-03 2015-08-26 Senju Pharmaceutical Co., Ltd. Corneal perception recovery drug containing amide compound
TWI367098B (en) 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
US20080269249A2 (en) * 2004-12-27 2008-10-30 Alcon, Inc. Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
US20090029970A1 (en) * 2005-02-16 2009-01-29 Astellas Pharma Inc. Pain remedy containing rock inhibitor
WO2006137368A1 (ja) * 2005-06-21 2006-12-28 Kowa Co., Ltd. 緑内障の予防又は治療剤
PT1905452E (pt) 2005-07-12 2013-07-16 Kowa Co Agente para a prevenção ou tratamento do glaucoma
CA2620818A1 (en) 2005-09-02 2007-03-08 Astellas Pharma Inc. Amide derivatives as rock inhibitors
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
KR20080077652A (ko) 2005-12-22 2008-08-25 알콘 리서치, 리미티드 로 키나제-매개 질환 및 증상 치료용 (인다졸-5-일)피라진및 (1,3-디하이드로인돌-2-온)피라진
US8227480B2 (en) 2006-06-08 2012-07-24 Ube Industries, Ltd. Indazole derivative having spiro ring structure in side chain
CN101495117B (zh) 2006-07-31 2012-08-15 千寿制药株式会社 含酰胺化合物的水性液体制剂
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
AR064420A1 (es) * 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
PL2107052T3 (pl) 2006-12-26 2012-05-31 Santen Pharmaceutical Co Ltd Nowa pochodna N-(2-aminofenylo)benzamidu posiadająca strukturę mocznikową
CN101646651A (zh) 2007-03-28 2010-02-10 参天制药株式会社 具有脲结构的新型吡啶羧酸（2-氨基苯基）酰胺衍生物
CA2680838A1 (en) 2007-03-28 2008-10-16 Santen Pharmaceutical Co., Ltd. Intraocular pressure-lowering agent comprising compound having histone deacetylase inhibitory effect as active ingredient
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA2697895C (en) * 2007-08-29 2017-10-31 Senju Pharmaceutical Co., Ltd. Agent for promoting corneal endothelial cell adhesion
US8372811B2 (en) * 2007-09-21 2013-02-12 Eyegene, Inc. Composition for treating retinopathy or glaucoma comprising thrombin derived peptides
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
US8267882B2 (en) 2008-03-05 2012-09-18 Ivantis, Inc. Methods and apparatus for treating glaucoma
ES2389754T3 (es) 2008-05-23 2012-10-31 Santen Pharmaceutical Co., Ltd Nuevos derivados de tiofendiamina con estructura urea
KR20110042054A (ko) * 2008-07-24 2011-04-22 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 축성 근시의 예방 또는 치료제
CN102099037A (zh) 2008-07-25 2011-06-15 旭化成制药株式会社 含有磺酰胺化合物的稳定的水溶液组合物
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
CA2737738A1 (en) * 2008-09-18 2010-03-25 Astellas Pharma Inc. Heterocyclic carboxamide compounds
US10842669B2 (en) 2008-11-13 2020-11-24 Gholam A. Peyman Ophthalmic drug delivery method
US10272035B2 (en) * 2008-11-13 2019-04-30 Gholam A. Peyman Ophthalmic drug delivery method
US20110125090A1 (en) * 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
ES2552386T3 (es) 2009-04-03 2015-11-27 F. Hoffmann-La Roche Ag Composiciones de {3-[5-(4-cloro-fenil)-1H-pirrol[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propano-1-sulfónico y usos de las mismas
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
AU2010271218B2 (en) 2009-07-09 2017-02-02 Alcon Inc. Ocular implants and methods for delivering ocular implants into the eye
WO2011006078A1 (en) 2009-07-09 2011-01-13 Ivantis, Inc. Single operator device for delivering an ocular implant
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011021221A2 (en) 2009-08-17 2011-02-24 Reliance Life Sciences Pvt. Ltd. Compositions for spinal cord injury
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
CN103249305A (zh) * 2010-07-27 2013-08-14 印斯拜尔药品股份有限公司 使用前药形式的激酶抑制剂化合物治疗眼科疾病的方法
TW202344254A (zh) 2011-02-04 2023-11-16 日商興和股份有限公司 青光眼或高眼壓症之預防或治療用之醫藥
AU2012214762B2 (en) 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
KR102074020B1 (ko) * 2012-07-13 2020-02-05 산텐 세이야꾸 가부시키가이샤 술폰아미드 화합물의 조합
US10617558B2 (en) 2012-11-28 2020-04-14 Ivantis, Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
EP2990040B1 (en) 2013-04-24 2019-12-04 Kyushu University, National University Corporation Therapeutic agent for eyeground disease
WO2016011056A1 (en) 2014-07-14 2016-01-21 Ivantis, Inc. Ocular implant delivery system and method
US9844556B2 (en) 2015-03-25 2017-12-19 Megumi Honjo Preventive/therapeutic method and preventive/therapeutic agent for complications after cataract surgery
JP6837475B2 (ja) 2015-08-14 2021-03-03 イバンティス インコーポレイテッド 圧力センサを備えた眼用インプラントおよび送達システム
EP4088719A1 (en) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
WO2017064119A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
WO2017106517A1 (en) * 2015-12-15 2017-06-22 Ivantis, Inc. Ocular implant and delivery system
TWI833535B (zh) 2017-12-21 2024-02-21 日商參天製藥股份有限公司 賽佩普斯特(Sepetaprost)及Rho激酶抑制劑之組合醫藥
CA3166602A1 (en) 2020-02-05 2021-08-12 Nicoletta Almirante Compositions for the treatment of glaucoma and ocular hypertension
US11918581B2 (en) 2021-01-11 2024-03-05 Incyte Corporation Combination therapy comprising JAK pathway inhibitor and rock inhibitor
WO2022150684A1 (en) 2021-01-11 2022-07-14 Ivantis, Inc. Systems and methods for viscoelastic delivery

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838677A (en) 1987-04-06 1989-06-13 Ayetech Inc. Eye exercising devices
US5250547A (en) 1991-08-29 1993-10-05 Syntex (U.S.A.) Inc. Benzopyran derivatives
CA2117096C (en) 1991-09-06 1997-11-04 Masafumi Arita 4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof
IL104755A0 (en) 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma
US5618955A (en) 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
IL103932A (en) 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
JP3066561B2 (ja) * 1993-10-07 2000-07-17 武田薬品工業株式会社 近視予防・治療剤
JPH07133225A (ja) * 1993-11-09 1995-05-23 Santen Pharmaceut Co Ltd 毛様体筋緊張緩和剤
EP1195372A1 (en) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
JPH08198876A (ja) * 1995-01-30 1996-08-06 Yoshitomi Pharmaceut Ind Ltd トランス−Ｎ−（１Ｈ−ピラゾロ〔３，４−ｂ〕ピリジン−４−イル）−４−グアニジノメチルシクロヘキサンカルボキサミド・１メタンスルホン酸塩・１水和物
US5888173A (en) 1995-08-10 1999-03-30 Singhal; Tara Chand Health saver computer break
JP3421217B2 (ja) * 1995-11-20 2003-06-30 麒麟麦酒株式会社 Ｒｈｏ標的タンパク質Ｒｈｏキナーゼ
US5906819A (en) 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
JPH09143099A (ja) * 1995-11-27 1997-06-03 Santen Pharmaceut Co Ltd 毛様体筋緊張緩和剤
ATE289815T1 (de) 1995-12-21 2005-03-15 Alcon Lab Inc Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
US5798380A (en) * 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
JPH10203982A (ja) * 1996-07-05 1998-08-04 Takeda Chem Ind Ltd 視機能障害の予防・治療剤
DK0956865T4 (da) * 1996-08-12 2010-11-22 Mitsubishi Tanabe Pharma Corp Medikamenter omfattende Rho-kinaseinhibitor

Also Published As

Publication number Publication date
DE69927936T2 (de) 2006-06-29
ES2372572T3 (es) 2012-01-23
EP1034793A1 (en) 2000-09-13
CN1494903A (zh) 2004-05-12
WO2000009162A1 (fr) 2000-02-24
EP1459743B1 (en) 2011-10-19
EP1459743A2 (en) 2004-09-22
EP1459742B1 (en) 2011-10-12
AU5198199A (en) 2000-03-06
EP1459742A3 (en) 2007-12-26
US20030125351A1 (en) 2003-07-03
JP3720264B2 (ja) 2005-11-24
KR20010015761A (ko) 2001-02-26
CN1195547C (zh) 2005-04-06
JP4490748B2 (ja) 2010-06-30
US6649625B2 (en) 2003-11-18
EP1034793B1 (en) 2005-10-26
ES2374518T3 (es) 2012-02-17
EP1459742B9 (en) 2012-05-02
EP1459743A8 (en) 2005-02-02
US6673812B1 (en) 2004-01-06
EP1459743B9 (en) 2012-08-01
CN1287494A (zh) 2001-03-14
ATE529102T1 (de) 2011-11-15
CA2307285A1 (en) 2000-02-24
KR100616466B1 (ko) 2006-08-29
HK1069121A1 (en) 2005-05-13
HK1069120A1 (en) 2005-05-13
ATE307609T1 (de) 2005-11-15
JP2004277432A (ja) 2004-10-07
CN1293878C (zh) 2007-01-10
EP1459742A2 (en) 2004-09-22
EP1459743A3 (en) 2007-12-26
CA2635412C (en) 2011-06-21
EP1034793A4 (en) 2003-07-09
DE69927936D1 (de) 2005-12-01
CA2307285C (en) 2009-03-31
ES2247822T3 (es) 2006-03-01
CA2635412A1 (en) 2000-02-24
ATE527993T1 (de) 2011-10-15

Similar Documents

Publication Publication Date Title
HK1030883A1 (en) Preventives/remedies for glaucoma
HK1015691A1 (en) Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia.
AU3196900A (en) Preventives/remedies for interstitial pneumonia and pulmonary fibrosis
BR0107591A (pt) Sistemas e processos para reduzir a pressão intraocular
TWI367098B (en) Treating agent for glaucoma
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2003005941A3 (de) Insert zur behandlung des trockenen auges
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
DE3872701T2 (de) Prostaglandin-derivate zur behandlung von glaucoma oder augenueberdruck.
TW200501949A (en) Ophthalmic compositions for treating ocular hypertension
WO2005020917A3 (en) Ophthalmic compositions for treating ocular hypertension
BR0210238A (pt) Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
BR0017158A (pt) Agonistas de 5ht2 para controlar a iop e tratar o glaucoma
MXPA03005922A (es) Metodo para tratar glaucoma ib.
EP1251862A4 (en) ORTHALMOLOGICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR HYPERTENSION
WO2004019874A3 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
EP1121932A4 (en) DRUGS FOR EYE DISEASES
EP0785193A4 (en) ARYLTHIADIAZOLE DERIVATIVES AND ANTIVIRAL PRODUCTS CONTAINING THEM
WO2002060339A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2003101379A3 (en) Pyranoindazoles and their use for the treatment of glaucoma
WO2002096317A3 (en) Method for treating glaucoma vi
DK0946503T3 (da) Nitromethylthiobenzenderivater som inhibitorer for aldosereductase
WO2004087051A3 (en) Ophthalmic compositions for treating ocular hypertension
MX9705379A (es) Uso de los 3,4-difenil-cromanos para la fabricacion de una composicion farmaceutica para el tratamiento o profilaxis vasodilatadora.

Legal Events

Date Code Title Description
CORR Corrigendum

Free format text: CORRECTED DATA OF SECTION 27 TO JOURNAL OF : [73] SENJU PHARMACEUTICAL CO., LTD. - 5-8, HIRANOMACHI 2-CHOME CHUO-KU - OSAKA-SHI, OSAKA 541-0046 - JAPAN - MITSUBISHI PHARMA CORPORATION - 6-9, HIRANOMACHI 2-CHOME CHUO-KU - OSAKA-SHI, OSAKA 541-0046 - JAPAN - DATED 29.9.2006

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140813